Alonso Krangle LLP Warns Actos Users of Yet Another Study Linking Actos to an Increased Risk of Bladder Cancer

Share Article

New Actos Bladder Cancer Study from the University of Pennsylvania Shows a Twofold to Threefold Increased Risk of Bladder Cancer Associated with Long-Term Use of Actos

News Image
Alonso Krangle LLP is now offering free lawsuit evaluations to anyone who developed bladder cancer while on Actos. Please contact us at 1-800-403-6191 or visit our website, www.FightForVictims.com.

Attorneys Andres Alonso and David Krangle, founding partners of Alonso Krangle LLP, a national law firm representing the victims of defective drugs, is warning users of the type 2 diabetes drug, Actos, that yet another study has found a strong association between long-term use of Actos and the development of bladder cancer. The study, which was conducted by researchers at the University of Pennsylvania and published in the Journal of the National Cancer Institute, found that long-term use of thiazolidinediones, a class of medications that includes Actos, was associated with a twofold to threefold increased risk of developing bladder compared to another class of diabetes drugs. [jnci.oxfordjournals.org/content/early/2012/08/08/jnci.djs328.abstract?sid=3b4f25a7-bf3f-49a7-871d-4db281deefa9]

Alonso Krangle LLP is now offering free Actos bladder cancer lawsuit evaluations to anyone who believes they developed bladder cancer side effects because of Actos or a related drug, including Actoplus Met, Actoplus Met XR and Duetact. To discuss a potential Actos bladder cancer lawsuit claim with one of the experienced and compassionate Actos lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.

According to this latest study, Actos and other thiazolidinediones are prescribed to some 15 million people, or roughly 20% of all type 2 diabetics in the U.S. Diabetics are already known to be at an increased risk for bladder cancer compared to the general population. The retrospective cohort study involved 18,459 patients who started treatment with Actos or another thiazolidinedione between July 1, 2000 and August 31, 2010, and 41,396 who began treatment with a sulfonylurea during the same period. From their analysis, the researchers concluded 170 patients per 100,000 who took Actos and similar drugs for at least five years would develop bladder cancer compared with 60 patients per 100,000 among those taking sulfonylurea drugs.

This is just the latest research to link Actos to an increased risk of bladder cancer. The U.S. Food & Drug Administration (FDA) issued a safety alert for Actos in June 2011, after a five-year interim analysis of an ongoing, ten-year epidemiological study of Actos linked the drug to a 40% increase in risk of developing bladder cancer. Among other things, the agency said Actos should not be used by people with active bladder cancer. [fda.gov/Drugs/DrugSafety/ucm259150.htm]

Actos has already been removed from the marketplace in France and Germany. In April, regulators in Canada issued an Actos bladder cancer warning similar to the FDA’s.
[medpagetoday.com/Endocrinology/Diabetes/26987;
hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/_2012/actos_3_pc-cp-eng.php]

Actos users from around the country who have been diagnosed with bladder cancer are now filing lawsuits alleging Takeda Pharmaceuticals failed to adequately warn patients and doctors about the drug’s association with bladder cancer. Late last year, the U.S. Judicial Panel on Multidistrict Litigation ordered that all Actos bladder cancer lawsuits filed in federal courts throughout the U.S. be consolidated in a multidistrict litigation and transferred to U.S. District Court for the Western District of Louisiana, in Lafayette, to be overseen by U.S. District Judge Rebecca Doherty (MDL 2299).

Alonso Krangle LLP continues to offer free legal evaluations to anyone who believes they developed bladder cancer because of Actos. To discuss a potential Actos bladder cancer lawsuit claim with one of the experienced and compassionate defective drug lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.

About Alonso Krangle LLP
Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on the handling of significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. A national law firm representing injured victims throughout the U.S., Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City and New Jersey.

For more information about Alonso Krangle LLP or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com

Contact: Alonso Krangle LLP
445 Broad Hollow Road
Suite 205
Melville, New York 11747
Toll-FREE 1-800-403-6191
Tel: 516-350-5555

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Krangle

Andres Alonso
Visit website